When skin reactions interrupt bone therapy: severe cutaneous adverse reaction to romosozumab leading to treatment discontinuation
Severe inflammatory skin reactions can occur at the romosozumab injection site, even in patients without a relevant allergic history.The detection of moderate or severe local inflammatory reactions allows for an adequate assessment of the risk-benefit balance of romosozumab treatment, which is essential for deciding whether to discontinue treatment and redirect bone-forming therapy.
Authors
- Luis Antonio Rodríguez-Arrieta (ORCID: https://orcid.org/0000-0001-9360-4943)
- Marisol Miranda Galvis (ORCID: https://orcid.org/0000-0003-4798-584X)
- José Manuel Álvarez Rodríguez
- Francisco Javier Suarez Contreras
- Samir Alexander Pantoja Meneses (ORCID: https://orcid.org/0000-0002-8141-6002)
Institutions
- Universidad del Norte (CO)
- University of Cartagena (CO)
- University of Sucre (CO)
- Universidad de Antioquia (CO)
- Clínica Santa María (CO)
Publication Details
- Journal
- European Journal of Case Reports in Internal Medicine
- Published
- 2025-08-25
- DOI
- https://doi.org/10.12890/2025_05719
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05